Regulatory Considerations for Oligonucleotide Drugs: Updated Recommendations for Pharmacology and Toxicology Studies-Reference-Cited by-同舟云学术

Regulatory Considerations for Oligonucleotide Drugs: Updated Recommendations for Pharmacology and Toxicology Studies

Published:1994-01 Issue:4 Volume:4 Page:299-301
ISSN:1050-5261
Container-title:Antisense Research and Development
language:en
Short-container-title:Antisense Research and Development

Author:

BLACK LAUREN E.,FARRELLY JAMES G.,CAVAGNARO JOY A.,AHN CHANG-HO,DeGEORGE JOSEPH J.,TAYLOR ALAN S.,DeFELICE ALBERT F.,JORDAN ALEXANDER

Publisher

Mary Ann Liebert Inc

Subject

Genetics

Link

http://www.liebertpub.com/doi/pdf/10.1089/ard.1994.4.299

Reference4 articles.

1. Regulatory Considerations for Evaluating the Pharmacology and Toxicology of Antisense Drugs

2. Complement Activation and Hemodynamic Changes Following Intravenous Administration of Phosphorothioate Oligonucleotides in the Monkey

3. Problems in Interpretation of Data Derived from in Vitro and in Vivo Use of Antisense Oligodeoxynucleotides

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overview of the Nonclinical Development Strategies and Class Effects of Oligonucleotide-based Therapeutics;A Comprehensive Guide to Toxicology in Nonclinical Drug Development;2024

2. Nucleic Acid Pharmaceutical Agents;Haschek and Rousseaux's Handbook of Toxicologic Pathology, Volume 2 : Safety Assessment Environmental Toxicologic Pathology;2023

3. Drug discovery: Chaos can be your friend or your enemy;Managing the Drug Discovery Process;2023

4. Preclinical Evaluation of Neuraxial Drugs for Safety;Neuraxial Therapeutics;2023

5. NONRODENT ANIMAL STUDIES;Drug Safety Evaluation;2022-12-23